What is the clinical efficacy of evantumumab?

Amivantamab (amivantamab-vmjw) is a bispecific antibody that is unique in that it targets both the epidermal growth factor receptor (EGFR) and the MET receptor. The main application for this drug is in patients with non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations. This mutated form is relatively rare in NSCLC but can be extremely challenging to treat.

In a clinical trial, evantumumab demonstrated efficacy. The study focused on patients with NSCLC who had previously received platinum-based chemotherapy. Platinum-based chemotherapy is the standard first-line treatment for NSCLC, but its effect is not ideal for patients with EGFR exon 20 insertion mutations. Therefore, these patients require new treatment options after disease progression.

Evantumumab, as monotherapy, provides new hope for these patients. The study results showed that after receiving evantumumab treatment, approximately 37% of patients experienced significant tumor shrinkage. This efficacy assessment is based on body imaging techniques, such as CT or MRI scans, to measure changes in tumor size. Among patients whose tumors shrank, the average duration of response exceeded 12 months. This means that, for these patients, evantumumab is not only able to control disease progression in the short term but also has the potential to maintain its efficacy over a longer period of time.

Of course, the efficacy of any drug needs to be verified in a wider patient population. The current study results are valid, but more clinical trials are still needed to further confirm the efficacy and safety of evantumumab. In addition, for this group of patients, in addition to tumor shrinkage, other indicators such as quality of life and survival are also important aspects to evaluate the efficacy.